Response to "Tocilizumab therapy and COVID-19"
J Osteopath Med
.
2021 Sep 8;121(11):867-868.
doi: 10.1515/jom-2021-0212.
Author
Pallavi Bhargava
1
Affiliation
1
Division of Infectious Disease, Department of Internal Medicine, Henry Ford Health System, 2799 West Grand Blvd, Detroit, MI 48202, USA.
PMID:
34492174
DOI:
10.1515/jom-2021-0212
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal, Humanized
COVID-19 Drug Treatment*
Humans
SARS-CoV-2
Substances
Antibodies, Monoclonal, Humanized
tocilizumab